human platelet lysate – human platelet lysate – …€¦ · thierry burnouf (taipei ... current...
TRANSCRIPT
Human Platelet Lysate –
Current Standards and Future Developments Workshop organized by the Working Party
Cellular Therapies of the ISBT
March 22-‐23, 2018 Zurich, Switzerland Venue Blood Service Swiss Red Cross Zurich,
Rütistrasse 19, CH-‐8952, Zurich-‐Schlieren, Switzerland
Online Programme www.isbt-‐web.org Organizers Thierry Burnouf (Taipei, Taiwan)
Christian Gabriel (Linz, Austria) Reinhard Henschler (Zurich, Switzerland) Mickey Koh (London, UK) Katharina Schallmoser (Salzburg, Austria)
Conference Proceedings planned to appear in Vox Sanguinis (2018)
Congress Secretariate E-‐mail: [email protected]
Goals of the Meeting:
This Workshop will provide a forum for transfusion experts who manufacture the product, scientists who are investigating its therapeutic and cell culture potential to discuss the latest updates on the field, and also with the regulators on how to classify this blood derived product.
Ample time shall be provided for a highly stimulated discussion. Sponsors:
International Society for Blood Transfusion (ISBT); Maco Pharma Inc.; Cerus Europe BV; Cook Regentec; Regional Blood Service Swiss Red Cross Graubünden and Zurich. Target groups:
• Regulators • Manufacturers of HPL for laboratory or human cell therapy use • Blood establishments, Transfusion medicine specialists • Users and developers of ATMPs • Clinicians (Aesthetic, oral, trauma, plastic and orthopedic surgeons,
Dermatologists) • Researchers • Veterinarians
Start of Meeting: Thursday March 22, 09.30 AM End of Meeting: Friday March 23, 13.00 PM Participation fee: € 200 (including Thursday Dinner) Registration form: please send E-‐mail to: [email protected]
Hotel Addresses: please send E-‐mail to: [email protected]
Attendants: Limited to 40
Human Platelet Lysate –Current Standards and Future Developments
Workshop organised by the ISBT Cellular Therapies Working Party
March 22-23, 2018 Zurich, Switzerland
Venue Blood Service Swiss Red Cross Zurich, Rütistrasse 19, CH-8952, Zurich-Schlieren, Switzerland
Online Programme www.isbtweb.org
Organizers Thierry Burnouf (Taipei, Taiwan) Christian Gabriel (Linz, Austria) Reinhard Henschler (Zurich, Switzerland) Mickey Koh (London, UK) Katharina Schallmoser (Salzburg, Austria)
Conference Proceedings Planned to appear in Vox Sanguinis (2018)
Congress Secretariate E-mail: [email protected]
Goals of the Meeting:
The workshop will provide a forum for transfusion experts who manufac-ture the product, scientists who are investigating its therapeutic and cell culture potential and regulators on latest updates and how to classify the product.
Ample time will be provided for highly stimulated discussions.
Sponsors:
International Society for Blood Transfusion (ISBT); American Associa-tion of Blood Banks (AABB); Maco Pharma Inc.; Cerus Europe BV; Cook Regentec; PL Bioscience GmbH; Trinova Biochem GmbH; Regional Blood Services Swiss Red Cross Graubünden and Zurich.
Target groups:
• Regulators• ManufacturersofHPLforlaboratoryorhumancelltherapyuse• Bloodestablishments,Transfusionmedicinespecialists• UsersanddevelopersofATMPs• Clinicians(Aesthetic,oral,trauma,plasticandorthopedicsurgeons,
Dermatologists) • Researchers• Veterinarians
Start of Meeting: Thursday March 22, 09.30 AMEnd of Meeting: Friday March 23, 13.00 PM
Participation fee: € 200 (including Thursday Dinner)
Registration form: Send E-mail to: [email protected] Addresses: Send E-mail to: [email protected]: Limited to 40
4: How do we evaluate the product: Release Testing
Katharina Schallmoser, Salzburg What do we have to consider for Release Testing of GMP-grade HPL?
5: Clinical Use of HPL
Claudia Cohn, Minneapolis Platelet-Rich-Plasma, Clinical Efficacy and Quality Control
Jean-Jacques Lataillade, Clamart HPL for cell therapy applications
6: Other Platelet Products for Regenerative Use
Christian Gabriel, Vienna HPL Applications in Regenerative Medicine
7: How Can HPL be Regulated?
Wilson Bryan, FDA Regulation of HPL in the U.S.
Christian Schärer, Swissmedic (TBC) Regulation of HPL in Europe
8: Perspectives
Thierry Burnouf, Taipei Potential for New Therapies using Human Platelet Lysates
Topics and Speakers
1: Basic Science of Platelets and Their Potential to Regenerate
Alan Nurden, Bordeaux Platelet Physiology
2: How do we Standardise Production of HPL?
Jo-Anna Reems, Salt Lake City Defining a Pathway to Standardize Hu-man Platelet Lysate
Steve Harris, Indianapolis (title to be confirmed) Bruno Delorme, Lille A standardized human clinical grade
platelet lysate manufactured from a qua-lified and validated process of production
Olafur Sigurjonsson, Reykjavic Use of Intercept-Treated HPL
3: How do We Evaluate the Product: Pre-clinical Studies
Karen Bieback, Mannheim Evaluation of HPL for Expansion of Human MSCs